Turku

Researchers are studying the usefulness of 3D-printed tooth replicas combined with autotransplantation of teeth in children and young adults who need tooth transplantation. This study is designed to compare the 3D generated tooth replicas with the conventional methods to see if the new technology improves the surgical process and success of tooth transplantation. The study is led by Turku University Hospital and includes participants aged 9 to 23 years. Participants will undergo tooth autotransplantation surgery using either a 3D-printed tooth replica or a conventional procedure. Researchers will evaluate factors such as the duration of surgery and the degree of manipulation needed during the transplant procedure. They will also assess how well the transplanted tooth erupts and develops its roots over time. Participants will be followed for one year after surgery. During this time, clinical and radiological examinations will be performed to determine the health of the transplanted teeth. The main outcomes measured include the number of patients with healthy transplanted teeth at one year. This monitoring will help researchers understand the effectiveness of using 3D replicas in tooth autotransplantation.

Prostate cancer is the most common cancer among men in Finland, with up to 20% of cases being metastatic at diagnosis and causing significant mortality. Accurate initial staging is crucial for deciding the best treatment approach. Current recommended imaging methods like bone scintigraphy and whole body CT have low sensitivity for detecting metastasis. This trial evaluates a new imaging agent, 99mTc-MIP-1404, used in SPECTCT scans, which binds to the PSMA molecule found on prostate cancer cells and may improve detection accuracy. Participants are randomly assigned to one of two groups for comparison. The control group undergoes traditional imaging with bone scintigraphy and whole body CT. The experimental group receives these standard scans plus additional imaging using 99mTc-MIP-1404 SPECTCT and 18F-PSMA-1007 PETCT. The 99mTc-MIP-1404 is administered as a single intravenous dose. The study aims to determine if this new imaging method is superior in identifying local lymph node metastases and overall metastasis in men with high-risk prostate cancer. During the study, researchers assess the presence of metastases using various imaging techniques and compare their diagnostic accuracy. They evaluate true and false positive and negative rates, inter-rater agreement, and how imaging results influence treatment decisions. Participants are monitored at baseline, and their involvement includes multiple imaging sessions. The trial helps clarify if 99mTc-MIP-1404 SPECTCT can enhance prostate cancer staging and guide better treatment planning.

Researchers are evaluating the effectiveness and safety of an investigational drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer. The study includes two groups based on the level of HER2 protein in the tumor Cohort 1 with HER2 levels 1 or 2 who have been previously treated with immune checkpoint inhibitors, and Cohort 2 with HER2 level 3. The study aims to understand how well BNT323 or chemotherapy controls cancer progression and how the drug affects patients immune response and quality of life. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or chemotherapy drugs such as doxorubicin, paclitaxel, or docetaxel. In Cohort 2, participants will receive BNT323 alone. Treatments are given intravenously and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment, safety follow-up, efficacy follow-up, and a long-term survival follow-up lasting up to about 53 months. During the study, participants will undergo regular assessments including tumor evaluations, safety monitoring, and quality of life questionnaires. Researchers will measure progression-free survival in Cohort 1 and tumor response rate in Cohort 2. Safety is monitored by tracking adverse effects and drug levels in the body. Participants can expect to be followed for up to 53 months after treatment to assess long-term outcomes and survival.

Researchers are evaluating new treatments for advanced ovarian cancer in women who have completed initial surgery and chemotherapy. The study focuses on non-HRD positive ovarian cancer, comparing a targeted therapy called sacituzumab tirumotecan sac-TMT given alone or with bevacizumab, against standard care options such as bevacizumab maintenance or observation. The goal is to see if sac-TMT with or without bevacizumab can help patients live longer without their cancer worsening. Participants in the experimental group will receive sac-TMT through intravenous infusion on days 1, 15, and 29 of every 6-week cycle until the cancer progresses, side effects become prohibitive, or other reasons for stopping arise. They may optionally receive bevacizumab on days 1 and 22 of each cycle. The comparator group will either receive bevacizumab alone every 3 weeks for up to 22 courses or be monitored without active treatment. Supportive medications like steroid mouthwash and other rescue drugs are recommended before sac-TMT infusions. Throughout the study, participants will be regularly monitored for how long they live without their disease progressing, overall survival, side effects, and quality of life using specialized questionnaires. These assessments will continue for up to approximately 78 months. The study is randomized, with single masking, and led by Merck Sharp & Dohme LLC. Participants can expect regular visits for treatment and monitoring during this period.

Researchers are investigating a financial social work program called FinSoc designed to help families in Finland who face complex financial difficulties and have at least one child under 18. The study aims to support these families by improving their financial skills, reducing anxiety related to money, and enhancing overall well-being through a structured, research-based intervention. Families struggling with budgeting, debt repayment, and financial stress are invited to participate in this randomized controlled trial. The FinSoc program consists of five one-on-one sessions with a trained social worker. These sessions cover topics such as budgeting, emotional and relational aspects of money, financial decision-making, and building long-term financial capability. Families are randomly assigned to either receive the FinSoc intervention or continue with regular social work services. After the final measurements, the control group will receive a materials package to support financial capability. Participants will complete questionnaires at three points before the intervention, right after it ends, and three months later. These questionnaires assess financial literacy, financial anxiety, economic self-efficacy, and health-related quality of life. In addition to surveys, interviews with some families and social workers will explore their experiences with the program. Social workers will also provide feedback after each session to ensure the intervention is delivered as planned. The study seeks to improve daily life for families and contribute knowledge to social and economic well-being practices.

Researchers are studying a new drug called BAY 3547926 in people with advanced liver cancer known as hepatocellular carcinoma HCC that shows a specific protein called Glypican 3 GPC3. This is the first time BAY 3547926 is being tested in humans, aiming to understand its safety, how the body processes it, and to find the best dose for treating this advanced cancer. The study also explores how well the drug works to fight the cancer. BAY 3547926 is an antibody conjugate labeled with a radioactive agent that targets cancer cells directly. This radioactive part emits radiation that damages and kills cancer cells with minimal harm to nearby healthy tissues. Participants will be part of one of four study parts the first part tests different doses to identify a safe and effective level once found, more participants will receive that dose alone or with other treatments in the following parts. During the study, participants will have health check-ups and scans to monitor their condition. Blood and urine samples will be collected, and participants will be asked about their health and any problems they experience. The research team will watch for side effects and measure how the cancer responds to the treatment over a period of up to 60 months after the first dose.

Researchers are studying people with idiopathic pulmonary fibrosis IPF or progressive pulmonary fibrosis PPF who have previously taken nerandomilast in another study. The aim is to assess how well patients tolerate long-term treatment with nerandomilast and to evaluate whether it improves lung function and delays worsening symptoms, hospital visits, or death. This open-label extension trial is sponsored by Boehringer Ingelheim and focuses on treatment over an extended period. Participants take nerandomilast tablets for up to 1 year and 10 months while continuing their usual pulmonary fibrosis treatments. The study involves a single treatment group receiving the drug, and no placebo or comparison groups. Regular visits with doctors help monitor health and collect data during this extended treatment phase. Throughout the study, participants undergo regular lung function tests and health assessments to track any adverse events and changes in lung capacity. The main outcome measured is the occurrence of any adverse events for up to about 99 weeks. Secondary outcomes include changes in forced vital capacity and time to worsening of disease symptoms or hospitalization. The study includes ongoing safety monitoring with a total participation time of up to nearly two years.

Researchers are evaluating ODM-212, a drug being studied in a first-in-human, multi-site, open-label Phase 12 clinical trial involving adults with selected advanced solid tumors that cannot be treated with curative intent. The study aims to assess the safety and side effects of ODM-212 in patients who have cancers such as mesothelioma, lung carcinoma, colorectal cancer, and others with specific genetic alterations. This research is sponsored by Orion Corporation, Orion Pharma. Participants receive ODM-212 tablets at doses of 5mg andor 40mg. The study has two parts an initial dose escalation phase to find a safe dose, followed by a dose expansion phase that includes patients with solid tumors harboring specific genetic pathway alterations. Treatments are given orally, and dosing details are adjusted based on patient response and safety observations. During the study, participants will be monitored from the first dose until one year after the last study visit to track treatment-emergent adverse events and their severity. Regular assessments include physical exams, laboratory tests, and performance status evaluations. Participants must comply with the protocol and provide informed consent. The total study duration varies based on treatment and follow-up schedules.

This trial focuses on elderly patients aged 80 years or older, or those 75 years and older who are considered frail, with untreated diffuse large B-cell lymphoma DLBCL and related lymphoma subtypes. The study is a phase III, randomized, open-label, multicenter trial conducted in several countries including Sweden, Norway, Finland, Denmark, Italy, Australia, and New Zealand. It aims to compare the standard chemotherapy regimen R-miniCHOP with an experimental treatment R-pola-miniCHP, where vincristine is replaced by polatuzumab vedotin, to assess differences in outcomes for this patient population. Participants will be randomly assigned to one of two treatment groups. One group will receive R-mini-CHOP consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone over six 21-day cycles. The other group will receive R-pola-mini-CHP, which includes rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin instead of vincristine, also given over six 21-day cycles. Both treatments last approximately 18 weeks. The study includes a screening period lasting up to 4 weeks before treatment begins. During the study, participants will be followed for up to 36 months after completing treatment to monitor progression-free survival over two years. Researchers will evaluate disease progression and safety outcomes through regular assessments during and after the treatment period. Participants will provide informed consent and undergo evaluations including health status and disease measurements to ensure eligibility and monitor treatment effects throughout the trial.

Researchers are evaluating the effects of a triple therapy inhaler combining budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with Chronic Obstructive Pulmonary Disease COPD who have a higher risk for heart and lung events. This Phase III study is randomized, double-blind, and conducted at multiple centers, focusing on participants with COPD and elevated cardiopulmonary risk. Participants will receive either the triple therapy inhaler or the dual therapy inhaler, both administered twice daily. The study compares these two inhalers over a period of up to three years, monitoring for serious cardiac or COPD events. The trial includes careful evaluation of various heart and lung-related health events during this period. During the study, participants will be closely monitored through regular visits, assessments, and tests to measure lung function, heart events, and COPD exacerbations. Researchers will track the time until the first severe cardiac or COPD event and evaluate other cardiovascular and respiratory outcomes over up to three years. Participants will also be assessed for their ability to properly use the inhaler and adherence to the study protocol throughout the trial.